浙江震元(000705) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥496,363,705.48, a decrease of 44.40% compared to the same period last year[6] - The net profit attributable to shareholders was -¥203,778.74, reflecting a decline of 553.18% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,521,323.25, an increase of 22.02% compared to the previous year[6] - The company's operating revenue for the first nine months was ¥1,779,630,832.41, a decrease of 37.59% compared to ¥2,851,624,421.30 in the same period last year[10] - Total operating revenue for Q3 2025 was CNY 1,779,630,832.41, a decrease of 37.6% compared to CNY 2,851,624,421.30 in the same period last year[20] - Net profit for Q3 2025 reached CNY 56,044,792.17, an increase of 24.4% compared to CNY 45,017,860.97 in the previous year[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,030,760,366.78, down 11.35% from the end of the previous year[6] - The company's total assets as of Q3 2025 amounted to CNY 3,030,760,366.78, a decrease from CNY 3,418,794,511.15 in the previous year[18] - Total liabilities decreased to CNY 1,013,292,006.49 from CNY 1,457,032,752.65 year-over-year, reflecting a reduction of 30.5%[18] - Long-term borrowings increased to CNY 183,371,696.61 from CNY 129,407,150.35, representing an increase of 41.7%[18] Cash Flow - The company reported a significant decrease in cash flow from operating activities, down 80.90% to ¥30,029,046.04 year-to-date[6] - The net cash flow from operating activities was ¥30,029,046.04, down 80.90% from ¥157,193,398.98 in the previous year[11] - Cash inflow from operating activities totaled CNY 1,842,178,023.72, down from CNY 3,022,606,960.03 in the previous period, indicating a decline of 39.1%[23] - Cash outflow from operating activities was CNY 1,812,148,977.68, compared to CNY 2,865,413,561.05 in the previous period, a decrease of 36.8%[24] - Net cash flow from investing activities was CNY -228,802,327.43, worsening from CNY -206,815,940.69 in the previous period[24] - Cash flow from financing activities generated a net inflow of CNY 187,410,070.23, an increase from CNY 139,998,625.49 in the previous period[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,792, with the largest shareholder holding 24.93% of the shares[12] - The company's basic and diluted earnings per share were both -¥0.0006, a decrease of 700.00% year-on-year[6] - Basic and diluted earnings per share were both CNY 0.1678, compared to CNY 0.1304 in the previous period, reflecting a growth of 28.5%[22] Investments and Expenses - Investment income surged by 741.53% to ¥33,314,409.69 from ¥3,958,808.40, primarily due to gains from the subsidiary Zhenyuan Pharmaceutical's capital increase[10] - The company reported an increase in investment income to CNY 33,314,409.69 from CNY 3,958,808.40 year-over-year[21] - Research and development expenses for Q3 2025 were CNY 36,247,787.04, slightly down from CNY 38,373,338.24 in the previous year[21] - The company’s financial expenses improved by 49.81%, reducing to -¥2,048,897.46 from -¥4,082,143.65 due to decreased interest income[10] Other Information - The company has successfully launched the S1 production line for histidine products, marking a significant step in synthetic biology production capabilities[14] - The company has decided to terminate the issuance of shares to specific investors, which will not adversely affect its current operations[14] - The company did not undergo an audit for the third quarter financial report[25] - The company plans to implement new accounting standards starting from 2025[25]